Amdocs Limited (NASDAQ:DOX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $101.83.
DOX has been the subject of a number of research reports. Barclays lowered their target price on Amdocs from $113.00 to $111.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Oppenheimer boosted their price target on Amdocs from $98.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. StockNews.com downgraded Amdocs from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, Stifel Nicolaus initiated coverage on Amdocs in a research note on Wednesday, October 2nd. They issued a “buy” rating and a $100.00 price target for the company.
Check Out Our Latest Research Report on DOX
Amdocs Stock Up 1.0 %
Amdocs Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.479 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.29%. Amdocs’s dividend payout ratio (DPR) is currently 45.05%.
Hedge Funds Weigh In On Amdocs
Several hedge funds and other institutional investors have recently modified their holdings of DOX. Private Trust Co. NA boosted its position in Amdocs by 62.9% in the third quarter. Private Trust Co. NA now owns 303 shares of the technology company’s stock worth $27,000 after purchasing an additional 117 shares during the last quarter. Brooklyn Investment Group bought a new position in shares of Amdocs in the third quarter worth about $28,000. Catalyst Capital Advisors LLC bought a new stake in Amdocs during the 3rd quarter valued at approximately $55,000. GAMMA Investing LLC boosted its stake in Amdocs by 115.1% in the 3rd quarter. GAMMA Investing LLC now owns 800 shares of the technology company’s stock worth $70,000 after purchasing an additional 428 shares during the period. Finally, American National Bank purchased a new position in Amdocs during the second quarter valued at $76,000. Hedge funds and other institutional investors own 92.02% of the company’s stock.
Amdocs Company Profile
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Read More
- Five stocks we like better than Amdocs
- What Are the FAANG Stocks and Are They Good Investments?
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Williams-Sonoma Stock: Buy It and Never Let It Go
- Comparing and Trading High PE Ratio Stocks
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.